Liquid Chromatography Tandem Mass Spectrometry

液相色谱串联质谱法

• 批准号: 7595708
• 负责人: CHRISTINA C. WANG
• 金额: $ 48.74万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7595708
• 关键词: Arts; Biological Assay; Biomedical Research; Bone Diseases; California; Chemicals; Child; Clinical; Clinical Research; Core Facility; Diagnosis; Disease; Elderly; Endocrine; Equipment; Funding; HIV; Health Sciences; Hormonal; Hormones; Human; Immunoassay; Institutes; Institution; Joints; Kidney; Laboratories; Liquid Chromatography; Liquid substance; Los Angeles; Malignant Neoplasms; Mass Spectrum Analysis; Measurement; Measures; Medical center; Metabolic; Metabolic Bone Diseases; Metabolism; Methodology; Methods; Monitor; Morbidity - disease rate; Preparation; Protocols documentation; Reproducibility; Research; Research Institute; Research Personnel; Serum; Services; Sister; Technology; Translational Research; Underserved Population; United States National Institutes of Health; Universities; Vitamin Deficiency; Vitamins; Woman; mass spectrometer; men; patient population; programs; public health relevance; small molecule; tandem mass spectrometry

DESCRIPTION (provided by applicant): The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA Biomed) General Clinical Research Center (GCRC) is applying for a Liquid Chromatography Tandem Mass Spectrometer (LC-MS/MS) for the GCRC Core Laboratory and the Biomedical Mass Spectrometry Facility. The LC/MS/MS is requested to serve the needs of clinical and translational investigators at Harbor-LA Biomed and our sister institutions in Los Angeles (Cedars Sinai Medical Center (Cedars-Sinai), UCLA-Westwood, and the Charles Drew University of Health and Science (Drew)). The sharing of the services of this equipment is an important part of our preparation for a joint application for a Clinical and Translational Sciences Institute (CTSI) across the four sister institutions. To avoid duplication, increase efficiency and optimize utilization in the laboratory, the program and laboratories directors of the GCRCs at UCLA Westwood, Cedars-Sinai, Harbor-LA Biomed and Drew have agreed to designate the Harbor-UCLA GCRC Core Lab and Biomedical Mass Spectrometry facility as the central Endocrine and Metabolism Core Laboratory for all four CTSI institutions. Currently, the GCRC Core Laboratory provides hormone and vitamin analyses mostly by immunoassays. These methodologies have higher variance, poorer reproducibility and in many instances less accuracy than that obtained from LC/MS/MS. The challenges of clinical assays of small molecules in research include the requirements of high sensitivity and low limit of quantitation (LOQ) into the low fentomolar range. Such sensitivity is necessary in order to be able to accurately diagnose hormonal or vitamin deficiency and to monitor its treatment in men, women and children. Our current investigators include 6 major NIH users with 15 protocols, 9 NIH funded users and 6 other junior and funded investigators. These investigators are engaged in a wide spectrum of research spanning from metabolic bone diseases inflicting children and the elderly, hormonal deficiencies in men and women, hormone and non-hormone dependent cancers, co-morbidities of HIV disease and importantly, understanding mechanisms underlying these diseases. With expansion of validated assay portfolio we anticipate that we can support more than twice the research protocols. This application is strongly supported by all four participating institutions. The strengthening of the Core Facilities providing Mass Spectrometry Technology capability will also significantly enhance our ability to serve not only our institution but our sister institutions at UCLA, Cedars-Sinai, and Drew in Southern California and our diverse and often underserved patient population. PUBLIC HEALTH RELEVANCE: The Harbor-UCLA General Clinical Research Center is requesting the funding of a state of the art, high-throughput liquid chromatography tandem mass spectrometer to measure serum hormones and other metabolic products in human bodily fluids. This will allow the measurement of very small amounts of these hormones and chemicals with very high selectivity, accuracy and precision. The application of this method will support many investigators from LA BioMed, Cedars-Sinai, UCLA-Westwood and Drew University in the diagnosis and monitoring of treatment of many metabolic, endocrine, kidney an bone disease for our underserved population.

描述(由申请人提供)：洛杉矶生物医学研究所在港湾-加州大学洛杉矶分校医学中心(洛杉矶生物医学中心)一般临床研究中心(GCRC)正在为GCRC核心实验室和生物医学质谱学设施申请一台LC-MS/MS(LC-MS/MS)。LC/MS/MS是为了满足港湾-洛杉矶比奥德医院和我们在洛杉矶的姊妹机构(锡达斯-西奈医学中心、加州大学洛杉矶分校-韦斯特伍德分校和查尔斯德鲁健康与科学大学(DREW))的临床和翻译研究人员的需求。共享这一设备的服务是我们准备在四个姊妹机构中联合申请临床和翻译科学研究所(CTSI)的一个重要部分。为了避免重复、提高效率和优化实验室利用，加州大学洛杉矶分校韦斯特伍德分校、锡达斯-西奈分校、港湾-洛杉矶分校生物医学中心和德鲁分校的GCRC项目和实验室主任已同意将港湾-加州大学洛杉矶分校GCRC核心实验室和生物医学质谱学设施指定为所有四个CTSI机构的中央内分泌和代谢核心实验室。目前，GCRC核心实验室主要通过免疫分析提供激素和维生素分析。与LC/MS/MS相比，这些方法的方差更大，重现性更差，在许多情况下准确度更低。临床小分子分析在研究中面临的挑战包括要求高灵敏度和低定量限(LOQ)到低fentomol范围。这种敏感性是必要的，以便能够准确诊断荷尔蒙或维生素缺乏症，并监测其对男性、女性和儿童的治疗。我们目前的调查人员包括6名主要的NIH用户和15项协议，9名NIH资助的用户和6名其他初级和资助的调查人员。这些研究人员从事的研究范围广泛，从导致儿童和老年人的代谢性骨骼疾病、男性和女性的激素缺乏、激素和非激素依赖型癌症、艾滋病毒疾病的共病以及重要的是了解这些疾病的潜在机制。随着经过验证的分析产品组合的扩展，我们预计我们可以支持两倍以上的研究方案。这项申请得到了所有四家参与机构的大力支持。提供质谱学技术能力的核心设施的加强也将显著增强我们不仅为我们的机构服务的能力，还将显著增强我们为加州大学洛杉矶分校、锡达斯-西奈大学和南加州德鲁大学的姊妹机构以及我们多样化且往往服务不足的患者群体提供服务的能力。公共卫生相关性：港湾-加州大学洛杉矶分校综合临床研究中心正在申请资助一台最先进的高通量高效液相色谱串联质谱仪，用于测量人体体液中的血清激素和其他代谢产物。这将允许以非常高的选择性、准确度和精密度测量非常少量的这些激素和化学物质。这一方法的应用将支持来自洛杉矶生物医学、锡达斯-西奈大学、加州大学洛杉矶分校-韦斯特伍德分校和德鲁大学的许多研究人员诊断和监测许多代谢、内分泌、肾脏和骨骼疾病的治疗，以满足我们服务不足的人群的需求。